Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.06 CAD
Change Today 0.00 / 0.00%
Volume 340.0K
MOM On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 10:25 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

miraculins inc (MOM) Snapshot

Open
C$0.05
Previous Close
C$0.06
Day High
C$0.06
Day Low
C$0.05
52 Week High
01/26/15 - C$0.29
52 Week Low
08/24/15 - C$0.05
Market Cap
2.6M
Average Volume 10 Days
335.4K
EPS TTM
C$-0.09
Shares Outstanding
47.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MIRACULINS INC (MOM)

Related News

No related news articles were found.

miraculins inc (MOM) Related Businessweek News

No Related Businessweek News Found

miraculins inc (MOM) Details

Miraculins Inc., a medical diagnostic company, focuses on acquisition, development, and commercialization of diagnostic tests and risk assessment technologies for unmet clinical needs primarily in the United States and Canada. The company’s Scout DS non-invasive diabetes screening test is a non-invasive diabetes screening system that provides a method for diabetes screening based on detecting and measuring diabetes related biomarkers present in the skin; and PreVu non-invasive skin cholesterol point of care test is a non-invasive tool to assist with the risk assessment of coronary artery disease. The company was incorporated in 1998 and is based in Winnipeg, Canada.

Founded in 1998

miraculins inc (MOM) Top Compensated Officers

Chief Executive Officer, President and Non In...
Total Annual Compensation: C$216.7K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

miraculins inc (MOM) Key Developments

Miraculins Inc. Announces Supplemental Filing with U.S. FDA Related to De Novo Marketing Clearance Pathway of its Scout Device

Miraculins Inc. announced that it has made a supplemental filing with the United States Food and Drug Administration (FD) regarding its recent de novo pre-submission for its Scout device. The additional submission of documentation is part of the Company's ongoing dialogue with the FDA regarding the evaluation of the de novo process as a potential pathway for the marketing clearance of the Scout device as an aid in the identification of pre-diabetes. The de novo process is generally considered to be appropriate for 'novel' medical devices for which there are no legally marketed predicate devices, and whose risk profiles do not warrant the regulatory pathway known as a premarket approval (PMA), which is required of products considered to have the risk to public safety (Class III). The company is of the view that there is no predicate for the Scout device, and based on the feedback it has received from the FDA to date, the de novo process could provide the appropriate regulatory pathway for marketing clearance in the U.S.

Miraculins Inc. Executes Non-Binding Letter of Intent with New Leaf Health Ltd for the Exclusive Distribution of Scout DS Diabetes Screen into UK Workplace

Miraculins Inc. has executed a non-binding Letter of Intent with New Leaf Health Ltd, for the exclusive distribution of the Scout DS diabetes screen into the UK workplace. New Leaf has a large and growing roster of clients including multi-nationals such as British Airways, Airbus and Volvo. Under the LOI, the parties have acknowledged the general terms that will form part of a formalized agreement, including the award of exclusive distribution rights to New Leaf within the UK workplace wellness segment for a designated period of time with options for renewal, and New Leaf's commitment to a minimum purchase of Scout DS devices within the first year of screening operations. According to the terms of the LOI, Miraculins is also to receive an ongoing payment for every Scout DS test conducted in the UK and additional revenue through the provision of branded test consumables.

Miraculins Updates Market on Regulatory Progress in China for its Scout DS® Diabetes Screening Device

Miraculins Inc. announced that it has now completed all required preparations for the submission of its Scout DS® device for product testing in compliance with Chinese Food and Drug Administration (CFDA) requirements. Product testing, which must precede clinical trials in China, relates to a series of safety and operational tests that the CFDA testing center and its engineers decide are suitable for a medical device including electrical testing, biocompatibility testing, mechanical testing, stability testing, integrity testing, and other related tests to verify the device's specified operating parameters.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MOM:CN C$0.06 CAD 0.00

MOM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Health Discovery Corp $0.03 USD 0.00
Imperial Innovations Group PLC 497.50 GBp 0.00
MDxHealth €4.25 EUR +0.12
Myriad Genetics Inc $36.80 USD -0.76
Vermillion Inc $2.04 USD +0.0001
View Industry Companies
 

Industry Analysis

MOM

Industry Average

Valuation MOM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 106.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 62.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MIRACULINS INC, please visit www.miraculins.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.